Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2020/11/029406
CTRI/2020/11/029406
Active, not recruiting
未知

A randomized, double blind, cross over, single center study to evaluate the oral sensory attributes of placebo tablet coatings

Abbott Healthcare Pvt Ltd0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Abbott Healthcare Pvt Ltd
Status
Active, not recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Healthy adult volunteer between 18 and 75 years of age at the time of enrolment who the Investigator believes that he/she can and will comply with the requirements of the protocol (e.g. study assessment completion).
  • •2\.Female of childbearing potential must have a negative pregnancy test and be non\-lactating.
  • •3\.Subject with no systemic or local conditions or on any medications that might compromise the taste or smell
  • •4\.Subject who has never smoked, or who has smoked less than 100 cigarettes in his/her lifetime
  • •5\.Subject signs and dates the written informed consent
  • •6\.Agree to comply with the study procedures and requirements

Exclusion Criteria

  • •1\.Female patients who are pregnant or a nursing mother
  • •2\.Subject with any impairment in taste.
  • •3\.Subjects who are determined as being the risk group for COVID\-19 as per applicable national guidelines.
  • •4\.Subject who do not agree to comply with the study procedures
  • •5\.Subject who is allergic to EazyGlideTM or conventional (Opadry) coatings or to the constituents of placebo tablets

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A bioavailability study of turmeric extracts in healthy human adult subjects under fasting conditions
CTRI/2014/02/004391Exodus Research Acer16
Completed
Phase 3
To evaluate effect of KSM-66 Ashwagandha® Capsule (300 mg) in Management of Frailty in Older Adults
CTRI/2022/02/040554Ixoreal Biomed50
Active, not recruiting
Phase 1
A double-blind, randomized, cross-over, multi-center efficacy and safety study of ibuprofen plus hyoscine butylbromide for pain management due to primary dysmenorrhea
EUCTR2022-000843-57-BGRONTIS HELLAS S.A.54
Active, not recruiting
Not Applicable
A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects with Type 1 Diabetes MellitusType 1 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045238Term: Type I diabetes mellitus without mention of complication
EUCTR2009-012082-54-DEBIODEL inc.
Active, not recruiting
Phase 1
A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.
EUCTR2006-002468-24-BGF.Hoffmann-La Roche Ltd.228